Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.61 |
| ▸ | DRD1 | P21728 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.57 |
| ▸ | DHFR | P00374 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.47 |
| ▸ | FLT4 | P35916 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | RARB | P10826 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ATP6V1B2 | P21281 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | EDNRA | P25101 | 1/20 | 0.46 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14589001 | 0.92 | DPP4 (0.54) | DPP4CHRM2DRD1LMNAKDM4E | |
| SCHEMBL3126451 | 0.92 | DPP4 (0.58) | DPP4CHRM2DRD1LMNAKDM4E | |
| SCHEMBL3806171 | 0.91 | DPP4 (0.56) | DPP4CHRM2DRD1LMNAKDM4E | |
| SCHEMBL3132116 | 0.91 | DPP4 (0.56) | DPP4CHRM2DRD1LMNAKDM4E | |
| SCHEMBL3132121 | 0.91 | DPP4 (0.56) | DPP4CHRM2DRD1LMNAKDM4E | |
| SCHEMBL3810076 | 0.91 | DPP4 (0.58) | DPP4CHRM2DRD1LMNAKDM4E | |
| SCHEMBL3134210 | 0.90 | DPP4 (0.62) | DPP4CHRM2DRD1LMNAKDM4E | |
| SCHEMBL13355644 | 0.88 | DPP4 (0.54) | DPP4CHRM2DRD1LMNAKDM4E | |
| SCHEMBL3124361 | 0.88 | DPP4 (0.55) | DPP4CHRM2DRD1LMNAKDM4E | |
| SCHEMBL3137170 | 0.88 | DPP4 (0.55) | DPP4CHRM2DRD1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010056633-A2 | 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-20 | — | — | WO | claimed |
| US-20090156577-A1 | 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-18 | — | — | US | claimed |
| WO-2010056633-A2 | 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010056633-A2 | 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-20 | — | — | WO | disclosed |
| US-20090156577-A1 | 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-18 | — | — | US | disclosed |
| EP-1675852-B1 | 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES | JANSSEN PHARMACEUTICA NV (BE) | 2009-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156577-A1 | 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES | NQO2, QRFPR, NQO1 | DPP4 1254/4885CHRM2 67/4885DRD1 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.